drug repurposing – mycolab.ai

Editorial: Raising the bar: advancing therapeutic strategies for fighting communicable and noncommunicable diseases

mycolabadmin

Scientists are developing new ways to fight dangerous infections caused by bacteria, viruses, and drug-resistant pathogens. Recent discoveries include safer uses of existing drugs, better dosing strategies tailored to individual patients, and effective combination therapies that reduce antibiotic resistance. These advances represent important progress in treating serious infectious diseases like COVID-19, tuberculosis, and bacterial infections.

Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2

mycolabadmin

Scientists are searching for new treatments for COVID-19 by studying indole-containing compounds, which are found in many plants and can be made in laboratories. Some approved drugs with indole structures, like the antiviral drug Arbidol, have been repurposed to fight COVID-19. Researchers are also designing new indole compounds and using computer simulations to predict which ones might work best against the virus’s key proteins.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing important minerals like zinc that these fungi need to survive. Testing showed nitroxoline was very effective against these fungi, even against strains that had developed resistance to modern antifungal drugs. This suggests nitroxoline could potentially be repurposed as a new treatment option for serious fungal infections.

Anticancer drugs targeting topoisomerase II for antifungal treatment

mycolabadmin

Researchers found that several anticancer drugs commonly used to treat human cancers can also effectively kill fungal infections, especially resistant strains of Candida. The most promising drug, idarubicin, works by targeting an essential enzyme in fungi called topoisomerase II, causing DNA damage and cell death. This discovery suggests a new strategy for treating serious fungal infections by repurposing existing cancer medications, particularly for patients with drug-resistant infections.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

This editorial highlights the growing problem of fungal infections that resist current treatments, causing millions of deaths worldwide each year. Researchers are finding new ways to fight these resistant infections by repurposing existing drugs in new combinations and discovering novel compounds from natural sources. The collection of studies presented shows promising results using combinations like minocycline with antifungal drugs, natural compounds like baicalin, and AI technology to predict resistance patterns. These innovative approaches offer hope for better treatment options for patients suffering from serious fungal infections.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing essential zinc that the fungus needs to survive. The study found that nitroxoline was highly effective against all tested fungal strains, including those resistant to modern antifungal drugs, suggesting it could be a promising alternative treatment for serious fungal infections.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against Aspergillus fungi that cause serious infections in immunocompromised patients. The drug works by removing zinc that the fungus needs to survive. The study found that nitroxoline was very effective against all tested fungal strains, including those resistant to modern antifungal drugs, suggesting it could potentially be repurposed as a new treatment option.

The Ptk2-Pma1 pathway enhances tolerance to terbinafine in Trichophyton rubrum

mycolabadmin

Researchers discovered that a protein called TrPtk2 helps dermatophytes resist terbinafine, a common antifungal medicine. They found that blocking this protein makes the fungus more susceptible to terbinafine. Additionally, they discovered that omeprazole, a stomach medication approved for human use, can be combined with terbinafine to make it more effective against resistant fungal infections.

Research Topic: drug repurposing